For In-vitro diagnostic use. RIDASCREEN® sIgA is an enzyme immunoassay for the quantitative determination of human secretory IgA (sIgA) in stool samples.
IgA is the most heterogeneous of all human immunoglobulins. IgA antibodies are present in external body fluids and form a major barrier of defense against pathogens. IgA occurs in monomeric (mIgA), polymeric (pIgA) and dimeric secretory form (sIgA). Secretory IgA (sIgA) consists of two monomeric IgA molecules, a J chain and a secretory component (SC). The secretory component is a polypeptide with a molecular mass of 70 kDa. The determination of fecal concentrations of sIgA can provide information about the functional status of gut-associated lymphoid tissue (GALT), which is the immune system of the intestine. sIgA is an indicator of the secretory performance and stimulation level of plasma cells in the intestinal submucosa. sIgA deficiency is reflective of decreased intestinal mucosal immune defense activity, whereas increased sIgA levels indicate that activity of the intestinal immune system is increased. Considering the strong anti-inflammatory properties of IgA, increased fecal concentrations of sIgA suggest the presence of local inflammatory responses in the intestinal mucosa.
Detection of sIgA in stool:
• Proof of impaired immunological barrier function of the intestinal mucosa (increased susceptibility to infection, allergic disease)
• Local inflammation of the intestinal mucosa
• Autoimmune diseases
|Test format||Microtiter plate with 96 wells (12 strips with 8 removable wells each)|
|Incubation time||approx. 135 min|
|Cut-off||Normal range: 100 – 1200 µg sIgA/g stool|
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com.